We are live on
!
Find out more
EI
EAM Investors Portfolio holdings
AUM
$866M
1-Year Est. Return
377.14%
This Fund
S&P 500
This Quarter
Est. Return
+113.09%
1 Year Est. Return
+377.14%
3 Year Est. Return
+5,228.32%
5 Year Est. Return
+49,813.07%
10 Year Est. Return
+19,957,621.5%
AUM
$452M
AUM Growth
+$130M
(+40%)
Cap. Flow
-$18.5M
Cap. Flow
% of AUM
-4.08%
Top 10 Holdings %
Top 10 Hldgs %
10.66%
Holding
352
New
147
Increased
15
Reduced
84
Closed
97
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AWH
Aspira Women's Health Inc. Common Stock
AWH
|
+$3.03M |
| 2 |
OneSpan
OSPN
|
+$2.96M |
| 3 |
Anterix
ATEX
|
+$2.79M |
| 4 |
Calix
CALX
|
+$2.73M |
| 5 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
+$2.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axsome Therapeutics
AXSM
|
+$3.54M |
| 2 |
Karyopharm Therapeutics
KPTI
|
+$3.44M |
| 3 |
Teladoc Health
TDOC
|
+$3.2M |
| 4 |
Krystal Biotech
KRYS
|
+$3M |
| 5 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
+$2.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.95% |
| 2 | Technology | 21.89% |
| 3 | Consumer Discretionary | 16.2% |
| 4 | Industrials | 10.05% |
| 5 | Consumer Staples | 6.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Atomera
ATOM
$206M
| $728K | 0.16% |
+80,864
| New | +$554K |
|
227
Helix Energy Solutions
HLX
$1.45B
| $728K | 0.16% |
+209,829
| New | +$568K |
|
228
OrthoPediatrics
KIDS
$586M
| $725K | 0.16% |
16,559
-23,503
| -59% | -$1.06M |
|
|
EVRI
229
DELISTED
Everi Holdings
EVRI
| $724K | 0.16% |
+140,216
| New | +$712K |
|
230
Acacia Research
ACTG
$451M
| $717K | 0.16% |
+175,241
| New | +$508K |
|
231
Brinker International
EAT
$9.75B
| $706K | 0.16% |
+29,411
| New | +$631K |
|
232
PAVmed
PAVM
$35.4M
| $706K | 0.16% |
743
-224
| -23% | -$224K |
|
233
Addus HomeCare
ADUS
$2.22B
| $697K | 0.15% |
7,532
-22,873
| -75% | -$1.98M |
|
234
Lincoln Educational Services
LINC
$1.25B
| $680K | 0.15% |
+174,305
| New | +$547K |
|
235
Cardiff Oncology
CRDF
$74.7M
| $643K | 0.14% |
+128,410
| New | +$263K |
|
236
Dyadic International
DYAI
$37.2M
| $639K | 0.14% |
+73,829
| New | +$491K |
|
237
WidePoint Corp
WYY
$106M
| $632K | 0.14% |
+90,839
| New | +$487K |
|
238
TELA Bio
TELA
$38.5M
| $585K | 0.13% |
+45,177
| New | +$593K |
|
239
Red Violet
RDVT
$950M
| $564K | 0.12% |
31,945
-139,554
| -81% | -$2.61M |
|
240
Stereotaxis
STXS
$135M
| $560K | 0.12% |
125,528
-76,543
| -38% | -$310K |
|
241
Ardelyx
ARDX
$1.2B
| $552K | 0.12% |
79,803
-330,931
| -81% | -$2.3M |
|
242
Innovative Solutions & Support
ISSC
$367M
| $547K | 0.12% |
109,452
-73,118
| -40% | -$321K |
|
|
BHR
243
Braemar Hotels & Resorts
BHR
$146M
| $542K | 0.12% |
+189,448
| New | +$550K |
|
|
MTEM
244
DELISTED
Molecular Templates, Inc.
MTEM
| $537K | 0.12% |
2,597
-2,984
| -53% | -$693K |
|
245
Century Casinos
CNTY
$33.5M
| $519K | 0.11% |
+124,994
| New | +$524K |
|
246
Veru
VERU
$37.1M
| $519K | 0.11% |
15,532
-15,840
| -50% | -$545K |
|
247
Astronics
ATRO
$3.75B
| $512K | 0.11% |
+58,153
| New | +$455K |
|
|
AXLA
248
DELISTED
Axcella Health Inc. Common Stock
AXLA
| $502K | 0.11% |
+3,628
| New | +$444K |
|
|
GSB
249
DELISTED
GlobalSCAPE, Inc.
GSB
| $501K | 0.11% |
51,401
| – | – |
|
250
Fulgent Genetics
FLGT
$510M
| $491K | 0.11% |
30,693
-137,209
| -82% | -$2.1M |
|
Similar funds
RWM
MCM
HP
OMG
ICCFIA
WFAL
WCM
TSS
EAM Investors's Q2 2020 Portfolio in Review
As of Q2 2020, EAM Investors held 352 positions worth $452M, up 40% from $322M the previous quarter. Its ten largest holdings account for 11% of the portfolio.
EAM Investors withdrew a net $18.5M in Q2 2020, closing 97 positions and reducing 84 holdings. Its most notable exit was Karyopharm Therapeutics, an estimated $3.44M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 40% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, EAM Investors opened a new position in Aspira Women's Health Inc. Common Stock worth $2.61M.
- EAM Investors's largest Q2 2020 buy was Aspira Women's Health Inc. Common Stock: 45,313 shares worth $2.61M.
- EAM Investors added most to Purple Innovation in Q2 2020, an estimated $2.04M increase.
- EAM Investors's biggest Q2 2020 reduction was Axsome Therapeutics, cutting an estimated $3.54M.
- EAM Investors fully exited Karyopharm Therapeutics in Q2 2020, selling an estimated $3.44M.
- EAM Investors's ten largest holdings make up 11% of its $452M portfolio in Q2 2020.
- EAM Investors opened 147 new positions and closed 97 in Q2 2020.
- EAM Investors's portfolio value rose 40% quarter-over-quarter to $452M.
Based on EAM Investors's 13F filing for Q2 2020, filed 13 Aug 2020.